Category Archives: Regenerative Medicine

SUNRISE, FL--(Marketwire - Dec 10, 2012) - Bioheart Inc. ( OTCQB : BHRT ) previouslyannounced that it is working with NorthStar Biotech to help promote regenerative medicine.NorthStar has announced that it will subsidize physicians to participate in the Ageless Regenerative Institute stem cell training program.The fully accredited CME training program includes a didactic lecture series followed by hands-on clinical training for physicians to learn to isolate stem cells for immediate use in their patients.The Ageless Regenerative Institute has successfully trained over 200 physicians and these physicians are utilizing both adipose and bone marrow derived stem cells as well as platelet rich plasma for orthopedics, aesthetics and other degenerative diseases.

With the new NorthStar/Bioheart program, this select group of physicians have the opportunity to receive full funding for the training and join a network of physicians who will offer in-clinic stem cell therapies.Once these physicians commence IRB-approved in-clinic services, Bioheart will receive royalties for the use of these fee-for-service procedures.Initial projections have not been announced by NorthStar.

"Physicians have for years evaluated and considered stem cell treatments as a potential alternative for a subset of our patient population.This program helps educate doctors and allows us a viable opportunity to expand our treatment portfolio for patients in need," said board-certified Miami internist Dr. Antonio Blanco.

Bioheart's president and CEO Mike Tomas said, "The training programs at the Ageless Regenerative Institute provide physicians with extraordinary regenerative medicine capabilities.We are fortunate to partner with Northstar to bring these therapies to the clinic."

Physicians interested in applying to participate in the program should contact info@agelessregen.com.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Ageless Regenerative Institute, LLC

The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research.ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more.ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy.For more information about regenerative medicine please visit http://www.agelessregen.com.

Originally posted here:
Bioheart in Partnership With NorthStar on Physician Training in Stem Cell Techniques

Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF
During in-vitro fertilization (IVF), physicians much choose among many embryos to pick the ones that are most likely to produce a successful pregnancy and health child. Shawn Chavez, PhD, a researcher at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, talks about an automated time-lapse recording system that can accurately detect which embryos are healthiest. She discusses new research showing that a parameter called "fragmentation" is important.From:institutesofmedicineViews:3 0ratingsTime:02:05More inEducation

Follow this link:
Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF - Video

Live Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Live cell therapy is one form of stem cell therapy under the hierarchy of cell therapy, which is under regenerative medicine. Live cell therapy was made popular since 1931 by Dr Paul Niehans, who pioneered the therapy using injection. Oral or injection live cell therapy is far more superior than surgical implantation due to several advantages. Today, live cell therapy has been applied to disease treatment, beauty and health rejuvenation. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:0 0ratingsTime:12:14More inScience Technology

The rest is here:
Live Cell Therapy | Stem Cell Malaysia - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/6kl7tg/stem_cell_and) has announced the addition of the "Stem Cell & Regenerative Medicine" book to their offering.

The potential use of stem cells in transplantation for the purpose of tissue regeneration is an exciting area of research currently undergoing rapid development. Implantation of human embryonic or autologous, ex vivo-expanded adult stem cells, particularly in older individuals, could circumvent the limited availability of organs/tissues as well as prevent complications related to immune rejection and disease transmission. Musculoskeletal tissue degeneration is closely associated with aging. Strategies employing autologous adult MSCs from older individuals for transplantation in order to regenerate their own ailing organ or tissues require that we vigorously define MSCs capacity to maintain growth potential and differentiation potential into the desirable cell lineages. We are currently restricted by the limited knowledge about physical parameters, such as biomechanical forces, that influence MSC growth and differentiation capacities. This is particularly important for MSCs isolated from older individuals, for whom little information is available.

This special volume aims to serve as an impetus in generating more interest among stem cell researchers and biotechnologists to improve and develop the cell-based therapies of damaged tissue using stem cells.

Topics Covered:

Foreword

Preface

Contributors

CHAPTERS

1 Justice and Vulnerability in Human Embryonic Stem Cell Research

Read more:
Research and Markets: Stem Cell & Regenerative Medicine

The World Stem Cell Summit - Dr. Yaszemski
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. Among them is Mayo Clinic Dr. Michael Yaszemski. In this video he talks about the summit, the emerging field of regenerative medicine and his unique military perspective.From:mayoclinicViews:5 1ratingsTime:04:16More inScience Technology

Read more:
The World Stem Cell Summit - Dr. Yaszemski - Video

World Stem Cell Summit - Terzic
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers. In this video, Dr. Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine addresses the importance of the summit and the emerging field of regenerative medicine.From:mayoclinicViews:6 0ratingsTime:05:34More inScience Technology

Read more:
World Stem Cell Summit - Terzic - Video

World Stem Cell Summit - Windebank
The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. In this video, Dr. Anthony Windebank talks about the emerging field of regenerative medicine.From:mayoclinicViews:7 0ratingsTime:03:39More inScience Technology

Read the original post:
World Stem Cell Summit - Windebank - Video

SUNRISE, FL--(Marketwire - Dec 4, 2012) - Bioheart Inc. ( OTCQB : BHRT ) previouslyannounced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market.Stemlogix has just announced the first ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

"The facilities at Bioheart Inc. are top notch and we are excited to move these new therapies for animals forward using state-of-the-art cGMP laboratories.We are fortunate to have the support and expertise of the Bioheart team," said Jason Griffeth, Chief Operating Officer of Stemlogix, LLC.

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

Bioheart's president and CEO, Mike Tomas said, "Bioheart is focused on commercializing cell therapies for cardiac patients and has many years' experience with a variety of different cell types.This partnership allows us to utilize our existing laboratories and expertise to bring these products to the veterinary market."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Stemlogix, LLC

Stemlogix high quality stem cell therapy and other regenerative medicine therapies are impacting the lives of cats, dogs and horses around the U.S. and in other countries. The company has developed a scientifically validated method for harvesting stem cells from both fat tissue and bone marrow for therapeutic use. The Stemlogix stem cell isolation processes provide for consistent cellular products that are compliant with current regulatory guidelines. Stemlogix has a highly experienced management team with over 20 years combined experience in developing multiple stem cell therapeutics for both human and animal use. In all of its products and services, Stemlogix aims to provide the best cutting-edge regenerative medical solutions, and seeks to provide companion animals and horses with renewed health and vitality. The company has partnered with Butler Schein Animal Health, the leading companion animal health distribution company in the U.S., who are demonstrating the ease and effectiveness of the Stemlogix regenerative medicine treatments to veterinarians nationwide. To learn more about Stemlogix, LLC and its wide range of innovative regenerative medicine products please visit http://www.stemlogix.com, send an email to info@stemlogix.com or contact your local Butler Schein Animal Health representative.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Read more here:
Update: Bioheart Partnership With Stemlogix Leads to First in U.S. Combination Regenerative Medicine Treatment on ...

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/6kl7tg/stem_cell_and) has announced the addition of the "Stem Cell & Regenerative Medicine" book to their offering.

The potential use of stem cells in transplantation for the purpose of tissue regeneration is an exciting area of research currently undergoing rapid development. Implantation of human embryonic or autologous, ex vivo-expanded adult stem cells, particularly in older individuals, could circumvent the limited availability of organs/tissues as well as prevent complications related to immune rejection and disease transmission. Musculoskeletal tissue degeneration is closely associated with aging. Strategies employing autologous adult MSCs from older individuals for transplantation in order to regenerate their own ailing organ or tissues require that we vigorously define MSCs capacity to maintain growth potential and differentiation potential into the desirable cell lineages. We are currently restricted by the limited knowledge about physical parameters, such as biomechanical forces, that influence MSC growth and differentiation capacities. This is particularly important for MSCs isolated from older individuals, for whom little information is available.

This special volume aims to serve as an impetus in generating more interest among stem cell researchers and biotechnologists to improve and develop the cell-based therapies of damaged tissue using stem cells.

Topics Covered:

Foreword

Preface

Contributors

CHAPTERS

1 Justice and Vulnerability in Human Embryonic Stem Cell Research

Go here to read the rest:
Research and Markets: Stem Cell & Regenerative Medicine

SUNRISE, FL--(Marketwire - Dec 3, 2012) - Bioheart Inc. (BHRT.QB) previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market.Stemlogix has just announced the first ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

"The facilities at Bioheart Inc. are top notch and we are excited to move these new therapies for animals forward using state-of-the-art cGMP laboratories.We are fortunate to have the support and expertise of the Bioheart team," said Jason Griffeth, Chief Operating Officer of Stemlogix, LLC.

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

Bioheart's president and CEO, Mike Tomas said, "Bioheart is focused on commercializing cell therapies for cardiac patients and has many years' experience with a variety of different cell types.This partnership allows us to utilize our existing laboratories and expertise to bring these products to the veterinary market."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Stemlogix, LLC

Stemlogix high quality stem cell therapy and other regenerative medicine therapies are impacting the lives of cats, dogs and horses around the U.S. and in other countries. The company has developed a scientifically validated method for harvesting stem cells from both fat tissue and bone marrow for therapeutic use. The Stemlogix stem cell isolation processes provide for consistent cellular products that are compliant with current regulatory guidelines. Stemlogix has a highly experienced management team with over 20 years combined experience in developing multiple stem cell therapeutics for both human and animal use. In all of its products and services, Stemlogix aims to provide the best cutting-edge regenerative medical solutions, and seeks to provide companion animals and horses with renewed health and vitality. The company has partnered with Butler Schein Animal Health, the leading companion animal health distribution company in the U.S., who are demonstrating the ease and effectiveness of the Stemlogix regenerative medicine treatments to veterinarians nationwide. To learn more about Stemlogix, LLC and its wide range of innovative regenerative medicine products please visit http://www.stemlogix.com, send an email to info@stemlogix.com or contact your local Butler Schein Animal Health representative.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Go here to see the original:
Bioheart Partnership With Stemlogix Leads to First in U.S. Combination Regenerative Medicine Treatment on Injured Horse